
FDA Peptide Compounding Vote: What It Actually Means
FDA Peptide Compounding Vote: What It Actually Means Short answer: The FDA peptide compounding vote in July 2026 did not make BPC-157, KPV, TB-500, MOTS-C, Semax, or Epitalon FDA-approved drugs. An FDA advisory committee recommended that those six peptide-related substances be considered for the Section 503A Bulks List. The recommendations are nonbinding, and FDA must […]
Read Article



